View in EDS

DDX5 (p68) and UbE2T as emerging superior cancer therapeutic targets: dual molecular glue target degradation by FL118 for conquering difficult-to-treat cancers.

Saved in:
Bibliographic Details
Title: DDX5 (p68) and UbE2T as emerging superior cancer therapeutic targets: dual molecular glue target degradation by FL118 for conquering difficult-to-treat cancers.
Authors: Li F; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. fengzhi.li@roswellpark.org.; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. fengzhi.li@roswellpark.org.; Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. fengzhi.li@roswellpark.org.; Canget BioTekpharma LLC, Buffalo, NY, 14203, USA. fengzhi.li@roswellpark.org., Ling X; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Canget BioTekpharma LLC, Buffalo, NY, 14203, USA., Chakraborty S; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Tang DG; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., McLean K; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Department of Gynecology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Wu W; Canget BioTekpharma LLC, Buffalo, NY, 14203, USA., Sule N; Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Vadehra D; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Fountzilas C; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Gupta A; Department of Pediatrics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Twist C; Department of Pediatrics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Ohm J; Department of Cancer Genetics & Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Chatta G; Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA., Abrams SI; Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.; Tumor Immunology & Immunotherapy Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
Source: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2026 May 18; Vol. 45 (1). Date of Electronic Publication: 2026 May 18.
Publication Type: Journal Article; Review
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966 (Electronic) Linking ISSN: 03929078 NLM ISO Abbreviation: J Exp Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1756-9966
DOI:10.1186/s13046-026-03733-3